A Randomized, Double-Blind, Phase 3 Study of Pemrbolizumab/Vibostolimab (MK-7684A) in combination with Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants with Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007)

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Eligibility

- Stage IV squamous or nonsquamous NSCLC - Confirmation that EGFR-, ALK-, or ROS1-directed therapy is not indicated as primary therapy - Has not received prior systemic treatment for metastatic NSCLC - Greater than or equal to 18 years of age - ECOG PS of 0 or 1 assessed within 7 days before randomization - Has a life expectancy of at least 3 months

Type of Study

Treatment

Locations

Greeley Campus
Harmony Campus
Medical Center of the Rockies
Poudre Valley Hospital

Principal Investigator
Photograph of Steven Schuster,  MD

Steven Schuster, MD

Study ID

Protocol Number: 22-0577

More information available at ClinicalTrials.gov: NCT05226598

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers